The FDA states new diabetes drugs now need to show a lack of cardiovascular toxicity. Despite initial reservations, companies are cooperating, and some are even seeking the holy grail of cardioprotection.
JNC 8 and ATP 4 are MIA. Should clinicians be POed? Here are explanation, speculation, and a little news about what all seem to agree is an unusually long delay in releasing NHLBI guidelines on risk-factor management.
Cardiovascular disease is the biggest epidemic the world has ever known, "bigger than HIV," affecting nearly one in three individuals. Given the magnitude of the epidemic and the ensuing worldwide shortage of cardiologists and specialists to treat cardiovascular morbidities, there is a need for new treatment paradigms, say researchers. That's where the polypill comes in.
Approximately 17 000 athletes from 200 countries have descended on London for the 2012 Olympic Games. Medical teams, including a staff of cardiologists, have been preparing for years to ensure the games go off without a hitch; the last thing anyone wants is an athlete dying of sudden cardiac arrest with the whole world watching.
A Cleveland-based company is offering a multibiomarker inflammation test that it claims offers "additive and complementary insight into an individual's risk for heart disease and cardiac events." Experts who spoke with heartwire agree there is an urgent need for simple, precise prediction tools, but whether the time has come for a multimarker blood test that patients can pay for out of pocket is hot-button issue.
Expiration of the clopidogrel patent draws a close to a "fascinating era" in cardiovascular medicine, say experts, having had its largest impact in the ACS and poststenting settings. Yet even as the patent expires there remain some unanswered questions, particularly given the emergence of platelet function and genetic testing for clopidogrel metabolism.
For people living with a left ventricular assist device, knowing a few simple tricks can make life a bit easier. Others with LVADs make good teachers, but increasingly, LVAD recipients are looking online for answers to their questions.
The poll was intended to assess physicians' concerns about the risk of diabetes in patients treated with statin therapy as well as the potential for cognitive changes; it is in response to recent labeling changes approved by the FDA. For both potential side effects, physician responses point to a disconnect between level of concern and what they are actually seeing in practice.
The Society of Vascular Surgery's decision to publish its own guidelines on management of extracranial carotid disease after already signing on to a multisociety guidance on carotid disease is not sitting well with leaders of some of the other professional societies.
A unique "medical mission" using handheld echo in a remote rural population in India is being hailed as a success after cardiologists around the globe logged on over a two-day period to read the echocardiograms of unseen patients half a world away.
The field of flavonoids and polyphenols continues to attract a massive amount of interest, from researchers and the public alike. But can health really be improved by eating chocolate and drinking red wine?
What made headlines in 2011? Everything from novel oral anticoagulants, blockbuster trials stopped early, and a new scrutiny on procedure appropriateness. heartwire reporters called up cardiologists across 11 different subspecialties to ask them what they thought the biggest news was in their field this past year.
Is elective angioplasty without surgical backup on-site safe and effective enough for the US? Where would you send a family member? Sparks flew on both sides of the debate, as captured in a survey conducted jointly by theheart.org and US News & World Report.
Global leaders in the fight against smoking stress that cardiologists and other physicians must become politically active to help counteract the immense power of the tobacco industry, which is constantly seeking to expand the number of smokers worldwide. Doctors have a voice, and they need to step out of their comfort zone and use it to effect change, say activists.
Asked what disease they fear most, people overwhelmingly list cancer over heart disease. In the last of a three-part series, heartwire looks at how much public support, fundraising, and volunteerism the two diseases have garnered in recent years and whether cancer's long stint in the limelight may be what's boosting research opportunities and new therapies as CVD lags behind.
Heart disease is the number-one killer in most of the Western world, followed closely by cancer. But a close look at just how much money is available to support research in both fields points to some striking disparities.
Heart disease is the number-one killer in most of the Western world, followed closely by cancer. But a close look at recent drug approvals and pipeline projects speaks to an explosion of new treatments for killer number two, while heart-disease treatments fall behind.
Attendance at a cardiac rehabilitation program after a cardiac event reduces the risk of death and future events, but uptake is notoriously low. Prohibitive costs, poor communication, and a laissez-faire attitude on the part of physicians are all a part of the problem.
It is now a month after the surprise announcement by the US National Heart, Lung, and Blood Institute that it was stopping the AIM-HIGH trial of extended-release niacin for patients with low HDL and high triglycerides because of futility. heartwire asked several lipid experts and general cardiologists if they had changed their practice since the disappointing, albeit preliminary, results were reported.
Where once they died young, these days most of the 1% of children worldwide born with congenital heart defects now survive to adulthood and need to be followed long term. The majority, however, fall off the radar when they become young adults, in part due to a lack of doctors skilled in adult congenital heart disease.
There's no subterfuge herethe ACC announced its new corporate partners back in 2010 and insists it has solid disclosure and protection policies in place. But as the second annual ACC CardioSmart Health Fair throws open its doors to some of America's highest-risk citizens, some are asking whether the hundreds of thousands of dollars donated by a fast-food restaurant and soda company, among others, lead to more harm than good.
The former vice president was recently implanted with a left ventricular assist device, but was it for bridge therapy, destination therapy, or "bridge to decision"? How suitable would he be for transplantation? Three expert observers discuss his case with heartwire.
Impressively capable for imaging and undeniable cool as technology, the current generation of smart-phone-sized ultrasound devices may be a leap forward for some uses, but experts warn they aren't a substitute for fully featured echo systems.
The situation has gotten so bad that one physician recently couriered quinidine to a colleague halfway around the world who couldn't access it in his own country. Should companies continue to make drugs known to be effective, even if doing so is not good business?
The growth of cardiac imaging is fueling concern over radiation exposure, especially for newer imaging modalities such as CT angiography and for so-called "episodes of care." Some experts are raising radiation alarms for other, older tests, while others point out that pinning down the true cancer risks from any type of test is more guesswork than science.